IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3377
Positioning
Market Dominance
Manufacturing
Medical Equipment
$4M
Brian M. Murphy
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. ... NanoVibronix' catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$FEED NanoVibronix, Inc. | 41 | 35 | 36 | 49 | - | - | -16.4% | -12.8% | 22.6% | -388.7% | -310.5% | -11.6% | 0.0% | 2.0x | $4M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
NanoVibronix, Inc. (FEED) receives a "Reduce" rating with a composite score of 41.3/100. It ranks #3377 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Brian M. Murphy
Chief Executive Officer
Labor Force
20
35
18
4
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for FEED
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for FEED.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -16.4% (sector -2.5%)
GM 23% vs sector 43%, OM -389% vs sector 1%
Capital turnover N/A, R&D intensity 76.9%
Rev growth -12%, 10yr history
Interest coverage -42.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
NanoVibronix, Inc. receives a Reduce rating from our analysis, with a composite score of 41.3/100 and 2 out of 5 stars, ranking #3377 out of 7,333 stocks. FEED's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
FEED's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -16.4% (sector avg: -2.5%), gross margins of 22.6% (sector avg: 42.5%), net margins of -310.5% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 36/100, FEED appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 0.07x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
NanoVibronix, Inc.'s investment score of 18/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -11.6% vs. a sector average of 5.9% and a return on assets of -12.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
FEED is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -11.6% year-over-year, while a beta of 6.76 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
NanoVibronix, Inc. registers a low stability score of 4/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 6.76 and a debt-to-equity ratio of 2.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 49/100 for FEED suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 6.76), micro-cap liquidity risk. With a $4M market cap (micro-cap), NanoVibronix, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
NanoVibronix, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3377 of 7,333 overall (54th percentile). Key comparisons include ROE of -16.4% trailing the -2.5% sector median and operating margins of -388.7% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While FEED currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (4) would have the largest impact on the composite score.
ROE 560% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 47% BELOW SECTOR MEDIAN
Op. Margin 30231% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate NanoVibronix, Inc. (FEED) as a Reduce with a composite score of 41.3/100 at a current price of $2.62. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (49th percentile) and value (36th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (4th percentile) and investment (18th percentile) tempers our overall conviction. We assign a No Moat rating (24/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
NanoVibronix, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.3/100 places it at rank #3377 in our full 7,333-stock universe. At $4M in market capitalization, NanoVibronix, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -12% combined with momentum at the 49th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 23% (-19.9pp vs sector) narrow to operating margins of -389% (-390.0pp vs sector) and net margins of -310.5%, yielding a gross-to-net conversion rate of -1373%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $2.62, NanoVibronix, Inc. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.1x, P/S of 1.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (2% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 41.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -12% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -310.5% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Below-average quality (35th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to NanoVibronix, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 6.76), current negative profitability (net margin -310.5%), below-average price stability (4th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 6.76); current negative profitability (net margin -310.5%); below-average price stability (4th percentile); weak quality scores (35th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 4th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (2% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate NanoVibronix, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-16.4%), negative profitability, weak asset returns (ROA -12.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — NanoVibronix, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, NanoVibronix, Inc. receives a Reduce rating with a composite score of 41.3/100 (rank #3377 of 7,333). Our quantitative framework assigns a No Moat (24/100, trend: widening), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on NanoVibronix, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign NanoVibronix, Inc. a meaningful economic moat, scoring 24/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 7.4/20.
The strongest moat sources are financial resilience (7.4/20) and reinvestment efficiency (7/20). Interest coverage -42.4x. Capital turnover N/A, R&D intensity 76.9%. These pillars form the core of NanoVibronix, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0.7/20) and margin superiority (3.6/20). ROE proxy -16.4% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~12240.3pp per year, and operating margin trajectory confirms strengthening economics. NanoVibronix, Inc.'s competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers include declining revenues (-12%) that pressure the earnings outlook. The margin cascade from 23% gross to -389% operating to -310.5% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 23%, operating margins of -389%, net margins of -310.5%. Return metrics include ROE of -16.4% and ROA of -12.8%. Relative to the Manufacturing sector, gross margins are 19.9 percentage points below the sector median of 43%, and ROE of -16.4% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 2%, revenue growth of -12%. The sector median D/E is 0%, putting NanoVibronix, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
High beta of 6.76 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081

ENvue Medical Inc. saw its shares jump by over 115% after announcing a distribution deal with U-Deliver for its reusable ENFit Syringes, which are designed for safer enteral feeding in home and long-term care settings. The proprietary syringes feature a unique twist-locking capability to prevent misconnections. This development underscores ENvue's focus on non-invasive medical technology, building on recent leadership appointments and market events.

ENvue Medical has signed a nationwide distribution agreement with U-Deliver for its over-the-counter reusable ENFit syringe line. The syringes, available in various sizes and reusable for up to seven days or 20 uses, meet ISO 80369-3 standards and aim to improve enteral care access in home and long-term care settings. This partnership is expected to significantly expand ENvue's presence in the non-acute enteral care market through U-Deliver's website, Amazon, and wholesale channels.

ENvue Medical (NASDAQ: FEED) has received a USPTO Notice of Allowance for a patent application covering a feeding tube that integrates an electromagnetic sensor with a distal-tip camera. This invention aims to provide real-time visualization and continuous positional tracking during placement, enhancing clinical confidence and reducing reliance on confirmatory procedures. The company believes this strengthens its intellectual property and competitive position in the enteral access market.
Technology supports the evolution of enteral access from blind procedures to real-time visualized placementTYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for the Company’s patent application titled “Feeding Tube with Electromagnetic Sensor and

NanoVibronix has completed its acquisition of ENvue Medical Holdings, a privately-held provider of enteral feeding solutions. The transaction, structured as a stock-for-stock exchange for 1,734,995 shares of NanoVibronix common stock, aims to strengthen the combined company's position in enteral feeding technology and therapeutic medical devices. A concurrent private placement investment of $500,000 was also secured, and the management team will see additions from ENvue while some current directors will resign.